Company Filing History:
1 out of 832,912 Years Active: 2001
Title: Athmani Salah: Innovator in Histamine Receptor Research
Introduction
Athmani Salah is a notable inventor based in Glasgow, GB. He has made significant contributions to the field of pharmacology, particularly in the development of novel chemical compounds targeting histamine receptors. His work has implications for therapeutic applications, showcasing the potential of his inventions in medical science.
Latest Patents
Athmani Salah holds a patent for "Imidazole derivatives as histamine receptor H3 (ANT) agonists." This patent details novel imidazole derivatives that function as histamine receptor H antagonists and/or agonists. The patent outlines the preparation of these compounds and their therapeutic uses. It also describes chemical compounds that can act as histamine receptor H agonists, partial agonists, or antagonists, with a general formula (Ia) or (Ib). The methods for revealing the agonist, partial agonist, or antagonist activity of such compounds in vivo are also disclosed. He has 1 patent to his name.
Career Highlights
Throughout his career, Athmani Salah has focused on innovative research that bridges chemistry and medicine. His work has contributed to a deeper understanding of histamine receptors and their role in various physiological processes. This research is crucial for developing new therapeutic strategies for conditions related to histamine signaling.
Collaborations
Athmani has collaborated with esteemed colleagues in his field, including Jean-Charles Schwartz and Jean-Michel Arrang. These collaborations have enhanced the scope and impact of his research, fostering advancements in the understanding of histamine receptors.
Conclusion
Athmani Salah is a prominent inventor whose work on histamine receptor research has the potential to influence therapeutic developments. His innovative approach and dedication to research continue to pave the way for future advancements in pharmacology.